|The role of reverse engineering in the development of generic formulations|
According to the FDA, a generic drug is identical, or bioequivalent, to a brand name drug in dosage, form, safety, strength, route of administration, quality, performance characteristics, and intended use.
The role of reverse engineering in the development of generic formulations
Though generics companies have used reverse engineering for quite some time, the topic is scarcely covered in the published literature. In this article, we discuss the importance of reverse engineering and propose a decision-making process for developing solid oral dosage forms. We suggest various components of reverse engineering and the tools needed to carry out the process. The method is based on information generated from a series of reverse engineering experiments on RLD products (4).
Components of reverse engineering
The next step is to quantify an identified excipient in the tablet matrix, which is challenging because of possible interference from the other excipients. Hence, the excipient must first be separated from the tablet matrix using techniques such as differential solubility, filtration (with filters of a specific pore size or molecular weight cutoff), high-performance liquid chromatography (HPLC), high-performance thin-layer chromatography (HPTLC), and size-exclusion chromatography. One must select the separation technique based on the number of interfering components present and their physicochemical properties.
After separation, quantification must be performed using a gravimetric or detection tool such as ultraviolet-visible light, the refractive index, an evaporative light-scattering detector for HPLC, or spectroscopic techniques (e.g. infrared attenuated transmittance reflectance or near-infrared [NIR] spectrometry). Gravimetry is best suited for quantifying major excipients of significant weight in the dosage unit. Components present in small quantities such as stabilizers, surfactants, and pH-modifying agents are best quantified using sophisticated separation and quantification techniques such as HPLC and HPTLC. High molecular weight excipients such as widely used polymers can be effectively quantified using size-exclusion chromatography.
Solid-state characterization of API
With respect to generic drug development and abbreviated new drug applications (ANDAs), polymorphism has been discussed thoroughly in recent publications (6). In the context of the regulatory requirements, the statutory provisions do not require the sponsor of an ANDA to demonstrate that the API in the generic product and the innovator product "exhibit the same physical characteristics and that the solid-state forms of the drug have not been altered" (7). Thus, solid polymorphism is not a relevant issue to demonstrate the basis of drug substance sameness in an ANDA.
In a practical context, the innovator product is usually developed using the most stable polymorphic form to avoid transformation complications during processing and storage. To be safe, generics companies should use the same polymorphic form as the RLD to ensure a similar stability and dissolution profile. At times, such a strategy will be blocked because a valid patent on the polymorphic form extends beyond the expiry of the basic molecule patent. In this instance, one must file under paragraph IV certification (505 [j] [A][vii]) and use an alternative solid form to develop the generic product. Various techniques such as powder X-ray diffraction, IR, NMR, Raman spectroscopy, etc.; differential scanning calorimetry; and themogravimetric analysis may be used to characterize solid forms. Detecting and quantifying polymorphic mixtures in the dosage unit may be required. This procedure can be conducted more effectively using powder X-ray diffraction because other techniques tend to exhibit interference from the tablet matrix.
Particle-size reduction or micronization is a common method used by pharmaceutical companies to improve the dissolution rate of poorly water-soluble drugs. API particle-size distribution which directly affects bioavailability and dissolution rate, helps ensure a bioequivalent formulation, especially for drugs having dissolution-sensitive bioavailabilities. Thus, the information generated from the API's particle-size distribution in the innovator product is critical in ensuring dissolution and bioequivalence. The challenge herein lies in determining the API's particle size in the presence of other excipients. Routine particle-sizing techniques based on light obscuration and laser scattering will not be applicable because of their inability to differentiate between the API and excipient particles. The only feasible technique is microscopy.
Microscopy can differentiate APIs from excipients on the basis of characteristics such as particle shape and birefringence patterns. Under polarized light, crystalline drugs exhibit birefringence patterns whereas many excipients are noncrystalline and therefore do not exhibit a birefringence pattern. Hot-stage microscopy can be supplemented with optical microscopy to confirm the API particles are identified according to their melting points. Thus, identifying and characterizing the original drug's API at the molecular and particle levels accelerates decision making and minimizes developmental and regulatory approval time.
Identifying the manufacturing process.
The process used to manufacture the RLD can be predicted on the basis of the API's physicochemical profile—the wet granulation process will not be feasible for water-sensitive APIs or it may be difficult to achieve and confirm the blend uniformity of a very low-dose API in a direct-compression method. Visual examination of the tablet fracture provides some idea about the granulation technique. Wet or dry granulation produce fractures that are rougher than those produced by direct compression. The tablet can be put in a petri dish containing water, and the disintegration pattern can be examined under a low-power optical microscope. Tablets prepared using direct-compression disintegrate into individual particles, whereas tablets prepared by wet or dry granulation disintegrate into particle agglomerates (granules). This information can be grouped with the qualitative formula to finalize the excipients' roles in the dosage form. Some excipients such as hydroxypropyl methylcellulose, starch, and lactose can have multiple roles in the final dosage form. Thus, it may be difficult to assign them a functionality initially by solely examining the qualitative formula.
Protocol for reverse engineering
Figure 1 shows a decision tree for performing reverse engineering on a tablet dosage form. The functionality of the excipient and the API's physicochemical properties strongly affect the amount of effort needed for reverse engineering to be successful.
A judiciously performed reverse engineering exercise can facilitate the decision-making process at various stages of product development (Figure 2).
During Stage 1, information about the API's solid form can expedite the identification of meaningful specifications and the selection of suitable vendors. Similarly, a highly truncated preformulation study protocol is needed for generic products that are qualitatively and quantitatively similar to the RLD.
Stage 2 will have the most perceptible effect on reverse engineering. Quantitative information about key ingredients will simplify prototype formulation optimization. A traditional approach involves making several prototypes of varying compositions and testing them for performance and stability.
Decoding the quantitative details would drastically reduce the number of experiments required to reach the optimal formulation. Thus, the decision-making process becomes objective because of reduced dependence on experimental observations such as the dissolution profile, which, though a useful tool, does not ensure a bioequivalent product. Much higher confidence about the bioequivalence can be obtained by developing a quantitatively similar product based on reverse engineering and ensuring a dissolution profile similar to the RLD. In the same way, proactive solid-state characterization of the API in the RLD would reduce risks along the developmental pathway, especially for products containing molecules in which the bioavailabilities are sensitive to dissolution.
From: Arvind K. Bansal, Vishal Koradia, Pharmaceutical Technology
|Chemicals and Raw Materials|
|Coating Application Equipment for Pipeline|
|Cooling Water System|
|Corrosion & Electrochemical Instruments|
|Corrosion Probes, Coupons and Holders|
|Industrial Coatings and Sealants|
|Laboratory Testing Services|
|Manufacturing and Process Equipment|
|Manufacturing Cells and Systems|
|Optical Components and Optics|
|Surface and Corrosion Protection Products|
|Test and Measurement Equipment|